Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling
Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.